Cediranib plus chemotherapy vs placebo plus chemotherapy
Overall survival · women with persistent, recurrent, or metastatic cervical cancer
Cediranib plus chemotherapy showed no clear difference in overall survival compared with placebo plus chemotherapy (low certainty).
1 finding from 1 review
- Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes onlyHR 0.94 [0.53, 1.65]1 study · 69 participantsLow